Amount of accrued additional upfront license fee.

No definition available.

Name:	lqda_AccruedAdditionalUpfrontLicenseFee
Namespace Prefix:	lqda_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Expiration term of the agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name:	lqda_AgreementExpirationTerm
Namespace Prefix:	lqda_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Initial term of submission of quarterly forecast of expected production considered as binding firm order.

+ References

No definition available.

+ Details

Name:	lqda_InitialTermOfSubmissionOfQuarterlyForecastOfExpectedProductionBindingFirmOrder
Namespace Prefix:	lqda_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The maximum future contingent milestones and royalties on net sales.

+ References

No definition available.

+ Details

Name:	lqda_MaximumFutureContingentMilestonesAndRoyalties
Namespace Prefix:	lqda_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The maximum potential development milestone payments per the agreement.

+ References

No definition available.

+ Details

Name:	lqda_MaximumPotentialDevelopmentMilestonePayments
Namespace Prefix:	lqda_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The maximum potential sales milestones to be paid.

+ References

No definition available.

+ Details

Name:	lqda_MaximumPotentialSalesMilestones
Namespace Prefix:	lqda_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of milestone payment for each additional indication approved by the FDA after PAH and PH-ILD and each additional product approved by the FDA under the license.

+ References

No definition available.

+ Details

Name:	lqda_MilestonePaymentForEachAdditionalIndicationOne
Namespace Prefix:	lqda_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of milestone payment for each additional indication approved by the PMDA after PAH and PH-ILD.

+ References

No definition available.

+ Details

Name:	lqda_MilestonePaymentForEachAdditionalIndicationThree
Namespace Prefix:	lqda_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of milestone payment for each additional indication approved by the EMA after PAH and PH-ILD.

+ References

No definition available.

+ Details

Name:	lqda_MilestonePaymentForEachAdditionalIndicationTwo
Namespace Prefix:	lqda_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of non-cancelable future commitments for product manufacturing and supply costs.

+ References

No definition available.

+ Details

Name:	lqda_NonCancelableFutureCommitmentForProductManufacturingAndSupplyCosts
Namespace Prefix:	lqda_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of cash outflow for upfront license fee.

+ References

No definition available.

+ Details

Name:	lqda_PaymentForUpfrontLicenseFee
Namespace Prefix:	lqda_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Term of submission of quarterly forecast of expected production.

+ References

No definition available.

+ Details

Name:	lqda_TermOfSubmissionOfQuarterlyForecastOfExpectedProduction
Namespace Prefix:	lqda_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_OtherCommitmentsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(17))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(25))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:	us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Details

Name:	us-gaap_OtherCommitmentsAxis=lqda_PharmosaLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementGeographicalAxis=srt_NorthAmericaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementGeographicalAxis=lqda_OtherThenNorthAmericaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_OtherCommitmentsAxis=lqda_ChasmTechnologiesAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=lqda_YutrepiaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_OtherCommitmentsAxis=lqda_AgreementWithLGMPharmaLLCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_OtherCommitmentsAxis=lqda_AmendedAndRestatedCommercialManufacturingServicesAndSupplyAgreementWithLonzaTampaLlcMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Commitments and Contingencies (Details) - USD ($) $ in Thousands			1 Months Ended	6 Months Ended
	Oct. 02, 2024	Jul. 14, 2023	Jun. 30, 2023	Jun. 30, 2025	Oct. 31, 2024
Commitments and Contingencies
Non-cancelable commitments for product manufacturing and supply costs				$ 14,200
Pharmosa License Agreement
Commitments and Contingencies
Upfront license fee to be paid			$ 10,000
Accrued additional upfront license fee					$ 3,500
Maximum potential development milestone payments	$ 37,750
Milestone payment for each additional indication approved by the FDA after PAH and PH-ILD and each additional product approved by the FDA under the license	10,000
Milestone payment for each additional indication approved by the EMA after PAH and PH-ILD	2,000
Milestone payment for each additional indication approved by the PMDA after PAH and PH-ILD	500
Pharmosa License Agreement \| North America
Commitments and Contingencies
Maximum potential sales milestones	185,000
Pharmosa License Agreement \| Other then North America
Commitments and Contingencies
Maximum potential sales milestones	$ 150,000
Chasm Technologies \| YUTREPIA
Commitments and Contingencies
Maximum future contingent milestones and royalties				1,300
Agreement With LGM Pharma, LLC
Commitments and Contingencies
Purchase Commitment, Remaining Minimum Amount Committed				$ 2,700
Expiration term of agreement				5 years
Amended and Restated Commercial Manufacturing Services and Supply Agreement with Lonza Tampa LLC
Commitments and Contingencies
Term of submission		24 months
Initial term		12 months